Sk3 Group Inc(SKTO)
USD --+0.00%
Reward46Moderate
Risk42Moderate
📊50%Data
Thin 0% profit margin
SKTO
+0.0 · +0.00%
USD · OTCCE
Sk3 Group Inc | Healthcare
Capital Destroyer
Market Cap:1.52M
ℹ️
Reward Rating
46
Moderate
Bottom 25% (model universe)
50% data coverage
ℹ️
Risk Rating
42
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on SKTO to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Sk3 Group Inc?

provides management advisory, licensing, and marketing services for medical marijuana collectives in California.

SKTO · Verdict

Moderate reward · moderate risk

SKTO stands out on volatility and balance sheet, but watch the profitability signal.

Based on 75% data coverage

SKTO · Verdict

What’s working & what to watch

Strengths 2

  • Volatility75/100

    Above average

  • Balance sheet68/100

    Current ratio 0.00

Watchouts 2

  • Profitability21/100

    0% return on equity

  • Cash flow45/100

    In line with peers

Model-based scoring. For information only — not financial advice.

What is Sk3 Group Inc?

provides management advisory, licensing, and marketing services for medical marijuana collectives in California. It licenses various products for marketing and sale, including the YAK line of medical marijuana edibles; Canna-Loz, a delivery system for large doses of phyto-cannabinoids; Yeti, a pre-roll for pain relief; and Dharmanol, a proprietary technology that extracts, stabilizes, and preserves the medicinal cannabinoids found in hemp and marijuana in their non-psychoactive form. The company is listed on the OTCCE in USA, operating in the Healthcare sector, with a market capitalisation of 1.52M.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (46)

The scoring profile indicates limited reward potential at this time, with valuation and growth offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap1.52M
P/E RatioN/A
Dividend YieldN/A
52 Week HighN/A
52 Week LowN/A
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares OutstandingN/A
No. of Employees15
IndustryDrug Manufacturers - Specialty & Generic
ExchangeOTCCE
Beta-24.906
CurrencyUSD
WebsiteN/A